Diamyd Medical agrees on new GABA/GAD study
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that the Company has signed an agreement with Uppsala University and Uppsala University Hospital to conduct a clinical study with the diabetes vaccine Diamyd® combined with one or several GABA-related substances for which the stem cell researcher Professor Per-Ola Carlsson will be the Principal Investigator.The planned researcher-initiated combination study will be discussed with the Swedish Medical Products Agency this spring and is the first of its kind where GABA combined with the diabetes vaccine Diamyd® will